Skip to content

Ejaculatory-Sparing HoLEP vs Standard HoLEP

Ejaculatory-sparing Holmium Laser Enucleation of the Prostate (HoLEP) vs Standard HoLEP: a Randomized Controlled Trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07631286
Enrollment
48
Registered
2026-06-08
Start date
2026-06-15
Completion date
2028-05-01
Last updated
2026-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Enlarged Prostate (BPH), Enlarged Prostate With Lower Urinary Tract Symptoms

Keywords

HoLEP

Brief summary

The objective of this study is to compare a new surgical technique for HoLEP that will allow for sparing of ejaculation post-HoLEP.

Detailed description

The primary aim of this study is to assess the efficacy of ejaculatory-sparing HoLEP (ES-HoLEP) in preserving ejaculation while also maintaining good urinary outcomes.

Interventions

OTHEREjaculatory-sparing (ES-sparing) HoLEP

The ejaculatory sparing technique involves sparing the distal apex of the prostate in particular the anterior portion of the prostate which will allow for coaptation necessary for antegrade ejaculation.

Sponsors

Northwestern University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
18 Years to 100 Years
Healthy volunteers
Yes

Inclusion criteria

\- Patients who are sexually active with antegrade ejaculation who are undergoing HoLEP for the treatment of bothersome lower urinary tract symptoms.

Exclusion criteria

* Patients with pre-existing retrograde ejaculation * Patients who are not sexually active * Patients with indwelling urinary catheter prior to surgery, neurological disease, or history of prior prostatic/urethral surgery that may impact ejaculation * Patients who lack decisional capacity * Patients unable to read/speak English

Design outcomes

Primary

MeasureTime frameDescription
Incidence of retrograde ejaculation1 yearPatient reported incidence of experiencing retrograde ejaculation
Ejaculatory satisfaction1 yearPatient reported satisfaction of ejaculation using Male Sexual Health Questionnaire - Ejaculatory Dysfunction (MSHQ-EjD) questionnaire. The MSHQ-EjD-SF evaluates the following parameters in regards to ejaculation: Frequency, Force, Volume and Bother (How much are you bothered by any ejaculation difficulties) on a 6-point Likert scale (typically scored 0 to 5). Interpretation: Higher scores indicate better ejaculatory function, while lower scores denote dysfunction and a greater level of personal distress regarding one's ejaculatory function.

Secondary

MeasureTime frameDescription
Sexual satisfaction1 yearPatient reported sexual satisfaction using the Sexual Health Inventory for Men (SHIM) questionnaire. The Sexual Health Inventory for Men (SHIM) contains 5 questions that is individually scored on a scale of 0 to 5. The SHIM score is calculated by adding up the scores of the 5 individual questions. Interpretation: Higher scores indicate better erectile function, while lower scores denote erectile dysfunction. A total score of 21 or less indicates that erectile dysfunction is present and should be addressed with a healthcare provider.
Urinary satisfaction1 yearPatient reported urinary satisfaction using the International Prostate Symptom Score (IPSS) questionnaire. The International Prostate Symptom Score (IPSS) is calculated by asking patients to rate 7 urinary symptoms over the past month on a scale from 0 to 5. These scores are simply added together to yield a total symptom severity score ranging from 0 to 35. An 8th question measures overall Quality of Life (QoL) but is not factored into the numerical total. Interpretation: the total score range is from 0 to 35. The total score indicates symptom severity: 0-7: Mildly symptomatic 8-19: Moderately symptomatic 20-35: Severely symptomatic

Countries

United States

Contacts

CONTACTAlyssa McDonald, MPH
alyssa.mcdonald@northwestern.edu312-695-8146
PRINCIPAL_INVESTIGATORAmy E Krambeck, MD

Northwestern University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 21, 2026